Opyl Ltd. (AU:OPL) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Opyl Limited has introduced ‘Trial Gen,’ a new module within its TrialKey platform that utilizes artificial intelligence to create tailored clinical trial protocols, promising to revolutionize the efficiency and success of clinical research. Boasting features that optimize trial characteristics and automate the design process, Trial Gen aims to save time and reduce costs for a broad spectrum of clients in the clinical research industry. The tool is versatile enough to support trials from inception or to offer guidance for ongoing research, ensuring broad applicability and scalability.
For further insights into AU:OPL stock, check out TipRanks’ Stock Analysis page.